European equities traded in the US as American depositary receipts kicked off the week slightly lower late Monday morning, declining 0.17% to 1,486.47 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet browser company Opera (OPRA) and medical device maker EDAP (EDAP), which rose 3.1% and 2.4%, respectively. They were followed by biotech firm Evaxion (EVAX) and biopharmaceutical company Genfit (GNFT), which advanced 2.1% and 1.6%, respectively.

The decliners from continental Europe were led by biopharmaceutical company argenx (ARGX) and pharmaceutical company Novo Nordisk (NVO), which dropped 2.3% and 1.4%, respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and 3D printer company Materialise (MTLS), which fell 1.2% and 1.1%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and biotech firm Autolus Therapeutics (AUTL), which increased 3.6% and 3.5%, respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Mereo BioPharma Group (MREO), which rose 2.5% and 1.3%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and pharmaceutical company Silence Therapeutics (SLN), which dropped 35% and 5.2%, respectively. They were followed by biotech firm Trinity Biotech (TRIB) and hospitality company InterContinental Hotels Group (IHG), which lost 2.6% and 2.1%, respectively.